<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857491</url>
  </required_header>
  <id_info>
    <org_study_id>2014MEKY034</org_study_id>
    <nct_id>NCT02857491</nct_id>
  </id_info>
  <brief_title>Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Comparison of Intravitreal Injection of Ranibizumab Versus Sham Injection Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy: a Single-center, Prospective Double-blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana
      vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal
      detachment. This study will compare intravitreal injection of anti-vascular endothelial
      growth factor (ranibizumab) versus sham injection before vitrectomy for PDR. The main focus
      is to see if pre-operative injection of ranibizuman can reduce peri-operative hemorrahge
      related complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eyes responding to panretinal photocoagulation can remain stable for decades, but incomplete
      responses and relapses can occur in a certain percent of diabetic patients showing as
      proliferative diabetic retinopathy. At present vitrectomy is the main intervention for those
      eyes with vitreous hemorrhage, proliferative membrane, and tractional retinal detachment. And
      the surgical procedure might be complicated because of intraoperative bleeding. And
      post-operative complications might be also involved. Perioperative use of intraocular
      anti-VEGF might be associated with less hemorrhage related complications and better visula
      acuity. This study will compare intravitreal injection of anti-vascular endothelial growth
      factor (ranibizumab) versus sham injection one week before surgery. The investigators tried
      to make sure whether pre-operative injection of ranibizuman can reduce reduce intra-operative
      bleeding, reduce the frequency of using endodiathermy, decrease surgical time, improve
      microcurculation of retina, and elevte best-corrected visual acuity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>perioperative hemorrhage of the surgical eye</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>size of retinal non-perfusion area assessed by fluorescene angiography</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular retinal thickness assessed with optical coherance tomography</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retinal vessel oxygen saturation measured with a retinal oximeter</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>best-corrected visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>complications</measure>
    <time_frame>3 months</time_frame>
    <description>other perioperative complications</description>
  </other_outcome>
  <other_outcome>
    <measure>surgical time</measure>
    <time_frame>1 day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>grade of surgical difficulty</measure>
    <time_frame>1 day</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Injection of 0.5 mg ranibizumabone week before vitrectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham intravitreal injection one week before vitrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>intravitreal injection of 0.5 mg ranibizumab before vitrectomy</description>
    <arm_group_label>ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sham</intervention_name>
    <description>sham intravitreal injection before vitrectomy</description>
    <arm_group_label>control</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pars plana vitrectomy</intervention_name>
    <description>surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.</description>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>vitrectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type I or type II diabetes

          -  there is clear indications for vitrectomy due to proliferative membrane in the
             vitreoretinal interface, mild hemorrhage, or tractional retinal detachment

          -  retinal large vessels could be detected within one PD away from the edge of optic disc
             by OCT

          -  microcurculation could be detected by FFA in at least one quadrant

          -  the patient could tolerant FFA examination

        Exclusion Criteria:

          -  a history of vitrectomy or scleral bucke in the included eye

          -  retinal laser photocoagulation treatment within 90 days in the included eye

          -  anti-VEGF treatment with 90 days in either eye

          -  there is cocurrent neovascular glaucoma in the included eye

          -  any reason that might hinde the procedure of vitrectomy, FFA OCT or the observation of
             ocular fudus

          -  a history of cere-brovascular accident or heart stroke

          -  renal failure

          -  could not attend follow up regularly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Lu</investigator_full_name>
    <investigator_title>Director of Fundus Disease Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

